CJM-112 is a humanized monoclonal antibody inhibitor that targets interleukin-17A (IL-17A). It holds potential for research in inflammatory diseases, such as hidradenitis suppurativa, which involve abnormalities in the IL-17A-related pathway.
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
